Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
The aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson's disease (PD). The study groups were consisted of 25 patients wi...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2009-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2009/132464 |
id |
doaj-d6550d7e82e94486ad37df400641d339 |
---|---|
record_format |
Article |
spelling |
doaj-d6550d7e82e94486ad37df400641d3392020-11-24T22:27:51ZengHindawi LimitedMediators of Inflammation0962-93511466-18612009-01-01200910.1155/2009/132464132464Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's DiseaseDeniz Tuncel0Fatma Inanc Tolun1Ismail Toru2Department of Neurology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, TurkeyDepartment of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, TurkeyDepartment of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, TurkeyThe aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson's disease (PD). The study groups were consisted of 25 patients with PD and 25 matched healthy subjects as a control. The NO level of patients in PD group (2.3±0.4 𝜇mol/L) was significantly lower than that in the control group (2.8±0.6 𝜇mol/L) (P:.011). Although there were no statistically significant differences in the GH, IGF-1, and IGF BP-3 levels among the two groups, in this preliminary study, we found low NO and mildly elevated IGF-1 levels in the patients with PD. The results may be associated with adaptation or protective mechanisms in the neurodegenerative disease processes such as seen in the PD. Further studies should be carried out to confirm our results.http://dx.doi.org/10.1155/2009/132464 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Deniz Tuncel Fatma Inanc Tolun Ismail Toru |
spellingShingle |
Deniz Tuncel Fatma Inanc Tolun Ismail Toru Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease Mediators of Inflammation |
author_facet |
Deniz Tuncel Fatma Inanc Tolun Ismail Toru |
author_sort |
Deniz Tuncel |
title |
Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease |
title_short |
Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease |
title_full |
Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease |
title_fullStr |
Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease |
title_full_unstemmed |
Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease |
title_sort |
serum insulin-like growth factor-1 and nitric oxide levels in parkinson's disease |
publisher |
Hindawi Limited |
series |
Mediators of Inflammation |
issn |
0962-9351 1466-1861 |
publishDate |
2009-01-01 |
description |
The aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson's disease (PD). The study groups were consisted of 25 patients with PD and 25 matched healthy subjects as a control. The NO level of patients in PD group (2.3±0.4 𝜇mol/L) was significantly lower than that in the control group (2.8±0.6 𝜇mol/L) (P:.011). Although there were no statistically significant differences in the GH, IGF-1, and IGF BP-3 levels among the two groups, in this preliminary study, we found low NO and mildly elevated IGF-1 levels in the patients with PD. The results may be associated with adaptation or protective mechanisms in the neurodegenerative disease processes such as seen in the PD. Further studies should be carried out to confirm our results. |
url |
http://dx.doi.org/10.1155/2009/132464 |
work_keys_str_mv |
AT deniztuncel seruminsulinlikegrowthfactor1andnitricoxidelevelsinparkinsonsdisease AT fatmainanctolun seruminsulinlikegrowthfactor1andnitricoxidelevelsinparkinsonsdisease AT ismailtoru seruminsulinlikegrowthfactor1andnitricoxidelevelsinparkinsonsdisease |
_version_ |
1725748724735410176 |